Eloralintide and tirzepatide combined for weight loss in adults with obesity
Tests eloralintide with tirzepatide for weight loss in adults with obesity.
Plain-language title generated from the registry record
Registry title: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Key facts
- Where
- Berlin, Bochum, Cologne, Essen, Gladbeck, Hamburg, Leipzig, Lübeck, Offenbach, Oldenburg, and Ratingen, GermanySee the 11 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who do not have diabetes. It compares a combined drug (eloralintide and tirzepatide) with tirzepatide alone, eloralintide alone and placebo for weight loss.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Obesity with a BMI of 35 kg/m2 or more at screening. No diabetes of any type.
- Earlier treatment
- At least 1 self-reported unsuccessful diet attempt to lose weight. Stable body weight (less than 5% change) for 90 days before screening. No glucose-lowering medication and no weight-loss medication or remedies in the 90 days before screening.
Main reasons for not taking part
- Type 1 diabetes, type 2 diabetes or any other type of diabetes
- Prior or planned surgery for obesity, with limited exceptions if done more than 1 year before screening
- Prior or planned endoscopic procedure or device-based therapy for obesity or type 2 diabetes, with an exception if the device was removed more than 6 months before screening
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospital stay for heart failure in the 90 days before screening
- New York Heart Association Class IV congestive heart failure
Read by machine on 13 November 2026.
Where in Germany
- FutureMeds BerlinBerlin, GermanyContact: Peter Hahn (principal investigator)No longer taking part
- Siteworks GmbH - BochumBochum, GermanyContact: Annemone Koechel (principal investigator)No longer taking part
- Zentrum fur klinische Forschung - KölnCologne, GermanyContact: Bastian Kirsch (principal investigator)No longer taking part
- InnoDiab Forschung GmbhEssen, GermanyContact: Gundega Sipola (principal investigator)No longer taking part
- Hausarztzentrum ButendorfGladbeck, GermanyContact: Zuhal Kundakci (principal investigator)No longer taking part
- Diabeteszentrum Hamburg WestHamburg, GermanyContact: Dominik Dahl (principal investigator)No longer taking part
- AmBeNet GmbHLeipzig, GermanyContact: Hans-Detlev Stahl (principal investigator)No longer taking part
- UKSH Campus Lübeck, Med. 1 - AG MeyhöferLübeck, GermanyContact: Svenja Meyhöfer (principal investigator)No longer taking part
- FutureMeds OffenbachOffenbach, GermanyContact: Christel Contzen (principal investigator)No longer taking part
- RED-Institut GmbHOldenburg, GermanyContact: Thomas Schaum (principal investigator)No longer taking part
- SANOS ClinicRatingen, GermanyContact: Jens Harmel (principal investigator)No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07881432EU 2026-526047-34-00
- Record updated
- 3 November 2026
- Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.Read full original descriptionShow less
A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
Inclusion: Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥35 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any glucose-lowering medication within 90 days of screening.